Cardiogen
Lab-Tested ≥98% Purity · Certificate of Analysis Included · Global Shipping
Cardiogen (Ala-Glu-Asp-Arg) — Cardiac Bioregulator Peptide for Cardiovascular Research
Cardiogen is a synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed at the St. Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson's research group. As a cardiac-specific bioregulator, Cardiogen has been characterized for its regulatory effects on myocardial gene expression and cardiomyocyte function. Published research in Bulletin of Experimental Biology and Medicine has demonstrated its capacity to normalize contractile function, restore metabolic enzyme expression, and promote cardiac tissue resilience in aged and ischemia-damaged myocardial models.
Mechanism of Action
Cardiogen operates via the characteristic Khavinson bioregulator mechanism—direct interaction with specific DNA sequences to modulate gene transcription in target tissues. The AEDR tetrapeptide binds complementary nucleotide sequences in promoter regions of cardiac-specific genes, including those encoding myosin heavy chain isoforms, troponin complex subunits, and mitochondrial respiratory chain enzymes. Research has demonstrated selective upregulation of cardioprotective heat shock proteins (HSP70, HSP27) and anti-apoptotic Bcl-2 family members in cardiomyocyte cultures.
Key Research Areas
- Myocardial Protection: In-vitro studies on isolated cardiomyocyte preparations have demonstrated that Cardiogen preserves contractile function and reduces lactate dehydrogenase release following simulated ischemia-reperfusion injury, suggesting direct cardioprotective activity.
- Cardiac Aging: Research in aged rodent models has shown that Cardiogen administration restores myocardial compliance parameters, normalizes diastolic filling indices, and preserves mitochondrial ultrastructure in cardiac tissue.
- Gene Expression Normalization: Microarray analysis of Cardiogen-treated cardiac tissue has revealed restored expression of age-dysregulated genes involved in calcium handling (SERCA2a, phospholamban), energy metabolism (CPT-1, PDH), and antioxidant defense.
- Fibrosis Modulation: Histological studies have documented reduced interstitial fibrosis and preserved capillary density in aged myocardium following chronic Cardiogen treatment, correlating with maintained TGF-β1/Smad signaling homeostasis.
Technical Specifications
- Dosage per vial: 10mg lyophilized powder
- Purity: ≥98% (HPLC verified)
- Sequence: Ala-Glu-Asp-Arg (AEDR tetrapeptide)
- Molecular Weight: 489.48 Da
- Storage: -20°C, protected from light
Why Researchers Choose Peptides BioLab
Every batch of Cardiogen supplied by Peptides BioLab undergoes rigorous HPLC and mass spectrometry analysis, ensuring ≥98% purity verified by an independent Certificate of Analysis (CoA). Our product is supplied as a lyophilized powder for maximum stability, shipped worldwide in temperature-controlled packaging.
Related Research Peptides
Researchers studying cardiac bioregulation and cardiovascular peptides may also find these compounds relevant: Thymalin, BPC-157, and SS-31. For a complete overview, browse our Recovery Research collection.
For research purposes only — Not for human consumption. All products are intended solely for in-vitro research and laboratory use.
Every Peptides BioLab product includes a Certificate of Analysis (CoA) with HPLC and MS data confirming ≥98% purity. The CoA is available in the product tabs as the 2nd image, or contact our team to request a copy.
Shipping: We ship worldwide from our state-of-the-art facilities. Orders are processed within 1–2 business days. Express and standard shipping options available at checkout.
Storage: Store lyophilized peptides at -20°C for long-term storage. Once reconstituted, store at 2–8°C and use within 30 days. Keep away from direct sunlight.
